Vani Parmar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Vani Parmar has a total of 167 co-authors. Here are the top co-authors by number of shared publications:
- Rajendra Badwe
Department of Surgical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, India
47 shared publications - Nita Nair
Apollo Hospital, Navi Mumbai, India
46 shared publications - Shalaka Joshi
Department of Surgical Oncology, Breast Services, Tata Memorial Hospital and Home Bhabha National Institute, Mumbai, India
46 shared publications - Rohini Hawaldar
Tata Memorial Centre, Mumbai, India
43 shared publications - Sudeep Gupta
Homi Bhabha National Institute, Mumbai, Maharashtra, India
43 shared publications - Vaibhav Vanmali
Tata Memorial Hospital, Mumbai, India
39 shared publications
Latest Publications
- 17 April 2026
- Published by Springer Nature in Indian Journal of Surgical Oncology
- Vol. 17 (10) , 2356-2361
Feasibility and Practical Application of “Axillary Reverse Mapping” – Experience from a Tertiary Care Cancer Centre
- 17 April 2026
- Published by Springer Nature in Indian Journal of Surgical Oncology
- Vol. 17 (10) , 2356-2361
Feasibility and Practical Application of “Axillary Reverse Mapping” – Experience from a Tertiary Care Cancer Centre
- Open Access
- 10 February 2026
- Published by Georg Thieme Verlag KG in Indian Journal of Radiology and Imaging
A Prospective Study on Diagnostic Accuracy of Breast Thermography over Conventional Breast Imaging (Mammography and Supplemental Ultrasonography) in Average-Risk Indian Women
The current recommendation for breast cancer screening is mammography. However, it has a high false negative rate, is less sensitive in dense breasts, and is associated with radiation exposure to the breast. Thermography measures body surface temperatures. In conventional thermography, the patient sits in front of the camera. Infrared images of the breast are captured in three views. Rotational thermography (Illumina360°) images with 360° views of one breast are obtained at a time in two different controlled temperatures when it is freely suspended. Primary: Descriptive study of thermographic images and correlation with routine conventional imaging (mammography and supplementary ultrasonography). Secondary: To assess the diagnostic accuracy of thermography with conventional work up as the gold standard. It is a prospective observational study. Inclusion criteria are positive finding on mammography and age 18 to 75 years. Patients who cannot lie in the prone position, patients who are unable to follow instructions, patients with fever, and pregnant and lactating women were excluded. Setting: tertiary cancer care center. Patients with unilateral positive mammography and contralateral negative mammography, where available, underwent thermography and findings from both modalities were compared. Sample size: 100 patients (198 breasts). The sensitivity of thermography in comparison to mammography was 83.87%, with specificity 10.81%, diagnostic accuracy 56.57%, positive predictive value 61.18%, and negative predictive value 28.57%. Thermography has high sensitivity and low specificity with a high false positive rate and thus a low diagnostic accuracy. It could not reliably differentiate benign from malignant lesions based on temperature risk stratification. Mammographic breast density and menstrual status did not have an effect on its ability to pick up lesions. However, specificity and diagnostic accuracy in premenopausal women imaged in the first half of menstrual cycle were more than those in the second half. If breast thermography is explored as a screening modality for early detection of breast cancer, its limitations can be a lower detection rate of smaller cancers and false positive uptake in high proportions of normal breasts.
- 10 February 2026
- Published by Georg Thieme Verlag KG in Indian Journal of Radiology and Imaging
Open AccessA Prospective Study on Diagnostic Accuracy of Breast Thermography over Conventional Breast Imaging (Mammography and Supplemental Ultrasonography) in Average-Risk Indian Women
The current recommendation for breast cancer screening is mammography. However, it has a high false negative rate, is less sensitive in dense breasts, and is associated with radiation exposure to the breast. Thermography measures body surface temperatures. In conventional thermography, the patient sits in front of the camera. Infrared images of the breast are captured in three views. Rotational thermography (Illumina360°) images with 360° views of one breast are obtained at a time in two different controlled temperatures when it is freely suspended. Primary: Descriptive study of thermographic images and correlation with routine conventional imaging (mammography and supplementary ultrasonography). Secondary: To assess the diagnostic accuracy of thermography with conventional work up as the gold standard. It is a prospective observational study. Inclusion criteria are positive finding on mammography and age 18 to 75 years. Patients who cannot lie in the prone position, patients who are unable to follow instructions, patients with fever, and pregnant and lactating women were excluded. Setting: tertiary cancer care center. Patients with unilateral positive mammography and contralateral negative mammography, where available, underwent thermography and findings from both modalities were compared. Sample size: 100 patients (198 breasts). The sensitivity of thermography in comparison to mammography was 83.87%, with specificity 10.81%, diagnostic accuracy 56.57%, positive predictive value 61.18%, and negative predictive value 28.57%. Thermography has high sensitivity and low specificity with a high false positive rate and thus a low diagnostic accuracy. It could not reliably differentiate benign from malignant lesions based on temperature risk stratification. Mammographic breast density and menstrual status did not have an effect on its ability to pick up lesions. However, specificity and diagnostic accuracy in premenopausal women imaged in the first half of menstrual cycle were more than those in the second half. If breast thermography is explored as a screening modality for early detection of breast cancer, its limitations can be a lower detection rate of smaller cancers and false positive uptake in high proportions of normal breasts.
- Top Cited PapersOpen Access
- 1 January 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (1) , 9-19
Addition of Carboplatin to Sequential Taxane-Anthracycline Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer: A Phase III Randomized Controlled Trial
PURPOSE: We evaluated the survival impact of adding platinum to standard taxane-anthracycline neoadjuvant chemotherapy in triple-negative breast cancer (TNBC). METHODS: In this phase III trial, patients with TNBC were randomly assigned, after stratification by stage and menopausal status, to receive neoadjuvant chemotherapy comprising once-per-week carboplatin (AUC-2) plus paclitaxel (100 mg/m 2 ) for 8 weeks, followed by four cycles of anthracycline plus cyclophosphamide, or same chemotherapy without carboplatin. The primary end point was event-free survival (EFS), and secondary end points were overall survival (OS) and pathologic complete response. This is the prespecified primary analysis of this study. RESULTS: Of 720 patients randomly assigned between April 2010 and January 2020, 717 (platinum 361, control 356) were included in modified intention-to-treat analysis. At median follow-up of 67.6 months, in platinum and control arms, there were 111/361 and 131/356 EFS events (hazard ratio [HR], 0.80 [95% CI, 0.62 to 1.03]; two-sided unstratified P = .081), with 5-year EFS of 70.7% (95% CI, 65.8% to 75.6%) and 64.1% (95% CI, 59.0% to 69.2%), respectively, and 94/361 and 121/356 deaths (HR, 0.74 [95% CI, 0.57 to 0.97]; nominal P = .029), with 5-year OS of 74.4% and 66.8%, respectively. In premenopausal patients, EFS (HR, 0.61 [95% CI, 0.43 to 0.84]; nominal P = .003; 5-year EFS 75.0% v 59.6%) and OS (HR, 0.57 [95% CI, 0.40 to 0.82]; nominal P = .002; 5-year OS 78.2% v 64.6%) were significantly higher, while in postmenopausal patients, EFS (HR, 1.19 [95% CI, 0.80 to 1.78]; nominal P = .386) and OS (HR, 1.06 [95% CI, 0.70 to 1.61]; nominal P = .772) were not significantly different, in platinum versus control arm. There was statistically significant interaction between study intervention and menopausal status for EFS and OS, with a benefit of adding platinum in premenopausal but not in postmenopausal patients. There was more grade ≥3 myelosuppression in carboplatin arm, but there was no difference in nonhematologic toxicities. CONCLUSION: Carboplatin did not significantly increase EFS but significantly increased the OS in patients with TNBC, with benefits confined to premenopausal patients.
- 1 January 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (1) , 9-19
Top Cited PapersOpen AccessAddition of Carboplatin to Sequential Taxane-Anthracycline Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer: A Phase III Randomized Controlled Trial
PURPOSE: We evaluated the survival impact of adding platinum to standard taxane-anthracycline neoadjuvant chemotherapy in triple-negative breast cancer (TNBC). METHODS: In this phase III trial, patients with TNBC were randomly assigned, after stratification by stage and menopausal status, to receive neoadjuvant chemotherapy comprising once-per-week carboplatin (AUC-2) plus paclitaxel (100 mg/m 2 ) for 8 weeks, followed by four cycles of anthracycline plus cyclophosphamide, or same chemotherapy without carboplatin. The primary end point was event-free survival (EFS), and secondary end points were overall survival (OS) and pathologic complete response. This is the prespecified primary analysis of this study. RESULTS: Of 720 patients randomly assigned between April 2010 and January 2020, 717 (platinum 361, control 356) were included in modified intention-to-treat analysis. At median follow-up of 67.6 months, in platinum and control arms, there were 111/361 and 131/356 EFS events (hazard ratio [HR], 0.80 [95% CI, 0.62 to 1.03]; two-sided unstratified P = .081), with 5-year EFS of 70.7% (95% CI, 65.8% to 75.6%) and 64.1% (95% CI, 59.0% to 69.2%), respectively, and 94/361 and 121/356 deaths (HR, 0.74 [95% CI, 0.57 to 0.97]; nominal P = .029), with 5-year OS of 74.4% and 66.8%, respectively. In premenopausal patients, EFS (HR, 0.61 [95% CI, 0.43 to 0.84]; nominal P = .003; 5-year EFS 75.0% v 59.6%) and OS (HR, 0.57 [95% CI, 0.40 to 0.82]; nominal P = .002; 5-year OS 78.2% v 64.6%) were significantly higher, while in postmenopausal patients, EFS (HR, 1.19 [95% CI, 0.80 to 1.78]; nominal P = .386) and OS (HR, 1.06 [95% CI, 0.70 to 1.61]; nominal P = .772) were not significantly different, in platinum versus control arm. There was statistically significant interaction between study intervention and menopausal status for EFS and OS, with a benefit of adding platinum in premenopausal but not in postmenopausal patients. There was more grade ≥3 myelosuppression in carboplatin arm, but there was no difference in nonhematologic toxicities. CONCLUSION: Carboplatin did not significantly increase EFS but significantly increased the OS in patients with TNBC, with benefits confined to premenopausal patients.
- 1 April 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 11 (11) , e2400507
Temporal Evolution in Patient-Reported Outcomes in Indian Women With Breast Cancer: A Longitudinal Study
PURPOSE: Breast cancer (BC) is the most common malignancy among women in India and globally. Given the high survivorship, understanding the evolution of health-related quality of life (HRQoL) is crucial, yet comprehensive longitudinal studies from India are lacking. PATIENTS AND METHODS: This prospective observational study included 500 patients with BC registered between June 2019 and March 2022. HRQoL was assessed at pretreatment, treatment completion, and 6-month follow-up using European Organisation for Research and Treatment of Cancer (EORTC)-QLQ-C30, EORTC-QLQ-BR-23, and EQ-5D-5L tools. A linear mixed-effects model analyzed HRQoL trajectories and predictors. RESULTS: The median patient age was 46 years, with 60.8% presenting with locally advanced disease; all patients underwent multimodal therapy, comprising surgery (57% mastectomy), chemotherapy (95%), and radiotherapy (RT; 77%). Pretreatment global QoL scores were influenced by age (younger fared better, P = .003), stage ( P = .027), and social displacement ( P = .038). Longitudinal assessment revealed a small decline in global QoL (–2.1) and EQ-VAS (–1.9), along with meaningful improvements in social (+12.8), cognitive (+4.3), and role function (+7.3). Symptom burden significantly decreased, except for deterioration in body image (–7) and sexual enjoyment (–16). Younger patients had slower recovery in physical ( P = .003) and social function ( P = .05), while school education and financial independence positively influenced QoL variation. Social displacement affected trajectories of QoL ( P = .017), role ( P = .032), and social function ( P = .024). Extent of surgery and RT did not affect overall HRQoL trends, although RT recipients reported more fatigue ( P = .029). CONCLUSION: To our knowledge, this is the first longitudinal HRQoL study in Indian patients with BC, showing significant improvement in most functional domains at early survivorship. Sociodemographic factors, such as age, social displacement, education, and financial independence, rather than treatment modalities, were stronger predictors of HRQoL. Longer follow-up is needed for a more comprehensive assessment.
- 1 April 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 11 (11) , e2400507
Temporal Evolution in Patient-Reported Outcomes in Indian Women With Breast Cancer: A Longitudinal Study
PURPOSE: Breast cancer (BC) is the most common malignancy among women in India and globally. Given the high survivorship, understanding the evolution of health-related quality of life (HRQoL) is crucial, yet comprehensive longitudinal studies from India are lacking. PATIENTS AND METHODS: This prospective observational study included 500 patients with BC registered between June 2019 and March 2022. HRQoL was assessed at pretreatment, treatment completion, and 6-month follow-up using European Organisation for Research and Treatment of Cancer (EORTC)-QLQ-C30, EORTC-QLQ-BR-23, and EQ-5D-5L tools. A linear mixed-effects model analyzed HRQoL trajectories and predictors. RESULTS: The median patient age was 46 years, with 60.8% presenting with locally advanced disease; all patients underwent multimodal therapy, comprising surgery (57% mastectomy), chemotherapy (95%), and radiotherapy (RT; 77%). Pretreatment global QoL scores were influenced by age (younger fared better, P = .003), stage ( P = .027), and social displacement ( P = .038). Longitudinal assessment revealed a small decline in global QoL (–2.1) and EQ-VAS (–1.9), along with meaningful improvements in social (+12.8), cognitive (+4.3), and role function (+7.3). Symptom burden significantly decreased, except for deterioration in body image (–7) and sexual enjoyment (–16). Younger patients had slower recovery in physical ( P = .003) and social function ( P = .05), while school education and financial independence positively influenced QoL variation. Social displacement affected trajectories of QoL ( P = .017), role ( P = .032), and social function ( P = .024). Extent of surgery and RT did not affect overall HRQoL trends, although RT recipients reported more fatigue ( P = .029). CONCLUSION: To our knowledge, this is the first longitudinal HRQoL study in Indian patients with BC, showing significant improvement in most functional domains at early survivorship. Sociodemographic factors, such as age, social displacement, education, and financial independence, rather than treatment modalities, were stronger predictors of HRQoL. Longer follow-up is needed for a more comprehensive assessment.
- Open Access
- 22 January 2025
- Published by Wiley in The Breast Journal
- Vol. 2025 (1) , 2997891
Management of Idiopathic Granulomatous Mastitis: Effectiveness of a Steroid‐Free Regimen Using Tinospora cordifolia —A Single‐Institution Experience
Introduction: Idiopathic granulomatous mastitis (IGM) is a benign, chronic inflammatory disease with no effective treatment and high relapse rate. The pathophysiology is poorly understood. Tinosporin, an immunomodulator obtained from Tinospora cordifolia , is known to be useful in treating immune‐mediated diseases. We report our experience of using Tinosporin for IGM and the effectiveness of this “steroid‐free” regimen. Methods: We analysed the clinicopathological characteristics of patients diagnosed with IGM on histopathology during January 2018 and December 2022. Tinosporin tablet (500 mg Guduchi stem extract) was prescribed for 3–6 months; data were collected from electronic medical records and analysed in SPSS v‐29. Results: Of 315 patients, 132 had complete clinical records. Median age was 39 years (25–77), and 107 (81.7%) were premenopausal. Seventy‐eight (59.09%) had clinical suspicion of malignancy. On imaging, 84 (63.64%) were BIRADS 4/5 lesions. Empirical broad‐spectrum antibiotics were prescribed to 101 patients. Tinosporin tablets were prescribed to 91 patients. Symptomatic response was seen in 72 (79.12%). Five patients did not achieve response, while 14 patients (15.38%) were lost to follow‐up. At a median follow‐up of 36 months (14–62 months), only 2 patients on Tinosporin had recurrence. None of the patients needed surgical intervention other than diagnostic biopsy or control of infection, and none received steroids. Conclusion: IGM is a benign, often self‐limiting disorder. However, it mimics malignancy in 60% cases, and histology clinches the diagnosis. We report the efficacy of steroid‐free management of IGM with immunomodulatory herbal origin phytopharmaceutical drug Tinosporin. It is safe, inexpensive and effective. Large volume excisions or mastectomies can be reserved for severe and refractory cases.
- 22 January 2025
- Published by Wiley in The Breast Journal
- Vol. 2025 (1) , 2997891
Open AccessManagement of Idiopathic Granulomatous Mastitis: Effectiveness of a Steroid‐Free Regimen Using Tinospora cordifolia —A Single‐Institution Experience
Introduction: Idiopathic granulomatous mastitis (IGM) is a benign, chronic inflammatory disease with no effective treatment and high relapse rate. The pathophysiology is poorly understood. Tinosporin, an immunomodulator obtained from Tinospora cordifolia , is known to be useful in treating immune‐mediated diseases. We report our experience of using Tinosporin for IGM and the effectiveness of this “steroid‐free” regimen. Methods: We analysed the clinicopathological characteristics of patients diagnosed with IGM on histopathology during January 2018 and December 2022. Tinosporin tablet (500 mg Guduchi stem extract) was prescribed for 3–6 months; data were collected from electronic medical records and analysed in SPSS v‐29. Results: Of 315 patients, 132 had complete clinical records. Median age was 39 years (25–77), and 107 (81.7%) were premenopausal. Seventy‐eight (59.09%) had clinical suspicion of malignancy. On imaging, 84 (63.64%) were BIRADS 4/5 lesions. Empirical broad‐spectrum antibiotics were prescribed to 101 patients. Tinosporin tablets were prescribed to 91 patients. Symptomatic response was seen in 72 (79.12%). Five patients did not achieve response, while 14 patients (15.38%) were lost to follow‐up. At a median follow‐up of 36 months (14–62 months), only 2 patients on Tinosporin had recurrence. None of the patients needed surgical intervention other than diagnostic biopsy or control of infection, and none received steroids. Conclusion: IGM is a benign, often self‐limiting disorder. However, it mimics malignancy in 60% cases, and histology clinches the diagnosis. We report the efficacy of steroid‐free management of IGM with immunomodulatory herbal origin phytopharmaceutical drug Tinosporin. It is safe, inexpensive and effective. Large volume excisions or mastectomies can be reserved for severe and refractory cases.
- Open Access
- 7 October 2024
- Published by Springer Nature in Indian Journal of Surgical Oncology
- Vol. 16 (2) , 576-580
Prevalence of Distant Metastases in High-Risk Operable Breast Cancer (HROBC) pT1-2 N2a or Higher at Diagnosis
Current standard guidelines do not recommend a routine staging workup in early operable breast cancer (OBC) as the incidence of de novo metastasis is only 1–2%. Some of these patients are at high risk for relapse based on the higher axillary nodal burden. This prospective study evaluated the presence of de novo asymptomatic distant metastases in HROBC with pT1/2 N2a/N3 on upfront surgery. A single-centre study was carried out in upfront operated OBC patients with four or more axillary nodes positive after definitive surgery. Comprehensive metastatic workup was carried out, including an ultrasound abdomen, bone scan, and CT scan (thorax-abdomen-pelvis) or PET scan before initiating adjuvant treatment. If a distant disease was detected, the adjuvant treatment intent was tailored accordingly. The study accrued a prospective consecutive cohort of 97 women with pT1-2 N2a-3 during 2015–2018 operated upfront for OBC with cT1-2 N0-1. Forty percent of women were premenopausal, 54 (55.6%) had pN2a, and 43 (44.3%) had pN3 disease. Distant disease was seen in 8 of 97 women (8.24%) of these high-risk early cancers, 5 had oligometastatic denovo disease (5.15%), and 3 had polymetastatic (3.09%). Between the 2 groups, the pickup rate of distant disease was higher in pN3 (11.4%) as against pN2a (5.6%), p = NS. Only 3.09% of patients with extensive metastases were treated with palliative intent. The study shows potential to optimize the management of HROBC with heavy nodal disease identified post-primary surgery by selective staging investigations, adequate resource stratification, and thereby improved management, including modifying treatment plans early.
- 7 October 2024
- Published by Springer Nature in Indian Journal of Surgical Oncology
- Vol. 16 (2) , 576-580
Open AccessPrevalence of Distant Metastases in High-Risk Operable Breast Cancer (HROBC) pT1-2 N2a or Higher at Diagnosis
Current standard guidelines do not recommend a routine staging workup in early operable breast cancer (OBC) as the incidence of de novo metastasis is only 1–2%. Some of these patients are at high risk for relapse based on the higher axillary nodal burden. This prospective study evaluated the presence of de novo asymptomatic distant metastases in HROBC with pT1/2 N2a/N3 on upfront surgery. A single-centre study was carried out in upfront operated OBC patients with four or more axillary nodes positive after definitive surgery. Comprehensive metastatic workup was carried out, including an ultrasound abdomen, bone scan, and CT scan (thorax-abdomen-pelvis) or PET scan before initiating adjuvant treatment. If a distant disease was detected, the adjuvant treatment intent was tailored accordingly. The study accrued a prospective consecutive cohort of 97 women with pT1-2 N2a-3 during 2015–2018 operated upfront for OBC with cT1-2 N0-1. Forty percent of women were premenopausal, 54 (55.6%) had pN2a, and 43 (44.3%) had pN3 disease. Distant disease was seen in 8 of 97 women (8.24%) of these high-risk early cancers, 5 had oligometastatic denovo disease (5.15%), and 3 had polymetastatic (3.09%). Between the 2 groups, the pickup rate of distant disease was higher in pN3 (11.4%) as against pN2a (5.6%), p = NS. Only 3.09% of patients with extensive metastases were treated with palliative intent. The study shows potential to optimize the management of HROBC with heavy nodal disease identified post-primary surgery by selective staging investigations, adequate resource stratification, and thereby improved management, including modifying treatment plans early.
- Open Access
- 4 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Surgical Tumor Resection Deregulates Hallmarks of Cancer in Resected Tissue and the Surrounding Microenvironment
Supplementary Figure 2 shows unsupervised clustering of Breast Cancer patients based on genome-wide expression counts.
- 4 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Surgical Tumor Resection Deregulates Hallmarks of Cancer in Resected Tissue and the Surrounding Microenvironment
Supplementary Figure 2 shows unsupervised clustering of Breast Cancer patients based on genome-wide expression counts.
- Open Access
- 4 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from Surgical Tumor Resection Deregulates Hallmarks of Cancer in Resected Tissue and the Surrounding Microenvironment
Supplementary Figure shows Venn diagram representation & heatmap for time-series microarray-based gene expression comparison between tumor-adjacent normal tissue at the start of surgery & tumor tissue obtained at various timepoints in head & neck cancer patients.
- 4 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from Surgical Tumor Resection Deregulates Hallmarks of Cancer in Resected Tissue and the Surrounding Microenvironment
Supplementary Figure shows Venn diagram representation & heatmap for time-series microarray-based gene expression comparison between tumor-adjacent normal tissue at the start of surgery & tumor tissue obtained at various timepoints in head & neck cancer patients.
- Open Access
- 4 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from Surgical Tumor Resection Deregulates Hallmarks of Cancer in Resected Tissue and the Surrounding Microenvironment
Supplementary Table 4 shows Genes deregulated in replicate analysis for breast cancer patients with their log-fold change values.
- 4 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from Surgical Tumor Resection Deregulates Hallmarks of Cancer in Resected Tissue and the Surrounding Microenvironment
Supplementary Table 4 shows Genes deregulated in replicate analysis for breast cancer patients with their log-fold change values.
- Open Access
- 4 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Surgical Tumor Resection Deregulates Hallmarks of Cancer in Resected Tissue and the Surrounding Microenvironment
Supplementary Table 1 shows the Breast cancer patient assay distribution and clinical info
- 4 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Surgical Tumor Resection Deregulates Hallmarks of Cancer in Resected Tissue and the Surrounding Microenvironment
Supplementary Table 1 shows the Breast cancer patient assay distribution and clinical info